Policosanol safely down-regulates HMG-CoA reductase - Potential as a component of the Esselstyn regimen

Medical Hypotheses

Volumn 59, Issue 3, 2002, Pages 268-279

  McCarty, M F ^a  

^a Pantox Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUANOSINE TRIPHOSPHATASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; STATIN;

CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIET SUPPLEMENTATION; DISEASE COURSE; DOWN REGULATION; DRUG COST; DRUG EFFECT; DRUG POTENCY; DRUG SAFETY; FOLLOW UP; FRACTURE; HEART INFARCTION; HUMAN; HYPERTENSION; ISOPRENYLATION; LONG TERM CARE; PHYSICIAN; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SENILE DEMENTIA; SIDE EFFECT; THROMBOCYTE;

ANIMALIA; ARUNDINARIA; SACCHARUM;

EID: 0036734326     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(02)00226-8     Document Type: Article

References (169)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
2. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
3. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
4. Can the clinical efficacy of the HMG CoA reductase inhibit effects on LDL-cholesterol?
5. Statins do more than just lower cholesterol
6. Direct vascular effects of HMG-CoA reductase inhibitors
7. HMG-CoA reductase inhibitor and risk of stroke
8. HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease
9. Beneficial effects of statins in coronary artery disease - Beyond lowering cholesterol
10. Direct vascular effects of HMG-CoA reductase inhibitors
11. Rho GTPases and signaling networks
12. Targeting Rho in cardiovascular disease
13. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors
14. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase
15. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase
16. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice
17. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation
18. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: Involvement of angiotensin AT1 receptor expression and Rac1 GTPase
19. Inhibition of isoprenoid biosynthesis and arterial smoothmuscle cell proliferation
20. 3-Hydroxy-3- methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1)
21. Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells
22. Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats
23. Simvastatin reduces monocyte-tissue-factor expression type IIa hypercholesterolaemia
24. Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages
25. Lovastatin inhibits gene expression of type-I scavenger receptor in THP-1 human macrophages
26. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins
27. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells
28. Role of nuclear factor-kappa B in atherogenesis
29. The nuclear factor-kappa B/ inhibitor of kappa B autoregulatory system and atherosclerosis
30. Modulation of vascular cell activation, function, and apoptosis: Role of antioxidants and nuclear factor-kappa B
31. Stroke, statins, and cholesterol A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors
32. Efficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for prevention of stroke
33. Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients
34. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
35. Statins and the risk of dementia
36. Alzheimer's disease A radical vascular connection
37. Vascular nitric oxide may lessen Alzheimer's risk
38. Vascular nitric oxide, sex hormone replacement, and fish oil may help to prevent Alzheimer's disease by suppressing synthesis of acute-phase cytokines
39. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo
40. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia
41. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril)
42. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia
43. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients
44. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women
45. Oral statins and increased bone-mineral density in postmenopausal women
46. Stimulation of bone formation in vitro and in rodents by statins
47. Increased amounts of farnesylated p21Ras in tissues of hyperinsulinaemic animals
48. Effect of insulin on farnesyltfransferase. Specificity of insulin action and potentiation of nuclear effects of insulin-like growth factor-1, epidermal growth factor, and platelet-derived growth factor
49. Insulin stimulates the phosphorylation and activity of farnesyltransferase via the Ras-mitogen-activated protein kinase pathway
50. Hyperinsulinemia potentiates activation of p21 Ras by growth factors
51. Insulin promotes phosphorylation and activation of geranylgeranyltransferase II. Studies with geranylgeranylation of rab-3 and rab-4
52. Effects of insulin on prenylation as a mechanism of potentially detrimental influence of hyperinsulinemia
53. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle
54. The Akt kinase signals directly to endothelial nitric oxide synthase
55. Insulin-stimulated activation of eNOS is independent of Ca++ but requires phosphorylation by Akt at Ser1 179
56. Free radical production in endothelial cells as a pathogenetic factor for vascular dysfunction in the insulin resistance state
57. Endothelium-specific activation of NAD(P)H oxidase in aortas of exogenously hyperinsulinemic rats
58. Insulin's stimulation of endothelial superoxide generation may reflect up-regulation of isoprenyl transferase activity that promotes Rac translocation
59. Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits
60. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes
61. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro
62. HMG CoA reductase inhibitor-induced myotoxicity: Pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture
63. Effect of policosanol on serum lipids and lipoproteins in healthy volunteers
64. Cholesterol-lowering effects of policosanol in rabbits
65. Cholesterol-lowering effect of policosanol on rabbits with hypercholesterolaemia induced by a wheat starch-casein diet
66. Carcinogenicity of policosanol in Sprague Dawley rats: A 24 month study
67. Teratogenic and reproductive studies of policosanol in the rat and rabbit
68. A 12-month study of policosanol oral toxicity in Sprague Dawley rats
69. Effects of policosanol chronically administered in male monkeys (Macaca arctoides)
70. Toxicity of policosanol in beagle dogs: One-year study
71. Carcinogenicity of policosanol in mice: An 18-month study
72. Multigeneration reproduction study of policosanol in rats
73. Evaluation of peri- and postnatal toxicity of policosanol in rats
74. Efficacy and safety of policosanol in patients with primary hypercholesterolemia
75. Effects of policosanol in elderly hypercholesterolemic patients
76. Effect of successive dose increases of policosanol on the lipid profile and tolerability of policosanol
77. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment
78. A two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinaemia
79. Treatment of hypercholesterolemia in NIDDM with policosanol
80. Effect of policosanol on hyperlipidemia and coronary heart disease in middle-aged patients A 14-month pilot study
81. Effects of policosanol in hypertensive patients with type II hypercholesterolemia
82. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors
83. Effects of policosanol on postmenopausal women with type II hypercholesterolemia
84. Effects of policosanol in older patients with type II hypercholesterolemia and high coronary risk
85. Comparative effects of policosanol and two HMG-CoA reductase inhibitors on type II hypercholesterolemia
86. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients
87. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus
88. Efficacy and tolerability of policosanol compared with lovastatin in patients with type II hypercholesterolemia and concomitant coronary risk factors
89. A long-term open-label study of the efficacy and tolerability of policosanol in patients with high global coronary risk
90. Effect of policosanol on the hepatic cholesterol biosynthesis of normocholesterolemic rats
91. Policosanol modulates HMG-CoA reductase activity in cultured fibroblasts
92. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3hydroxy-3-methylglutaryl-coenzyme A reductase
93. Isoprenoid-mediated inhibition of mevalonate synthesis: Potential application to cancer
94. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin
95. Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans
96. Effect of policosanol on platelet aggregation in healthy volunteers
97. Effect of policosanol successive dose increases on platelet aggregation in healthy volunteers
98. Comparative study of policosanol, aspirin and the combination therapy policosanol-aspirin on platelet aggregation in healthy volunteers
99. Effect of policosanol on platelet aggregation and serum levels of arachidonic acid metabolites in healthy volunteers
100. Effect of policosanol on platelet aggregation in type II hypercholesterolemic patients
101. A double-blind, placebo-controlled study of the effects of policosanol in patients with intermittent claudication
102. A long-term study of policosanol in the treatment of intermittent claudication
103. Long-term therapy with policosanol improves treadmill exercise-ECG testing performance of coronary heart disease patients
104. Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors
105. Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro
106. Effect of policosanol on intimal thickening in rabbit cuffed carotid artery
107. Triphasic sequence of neointimal formation in the cuffed carotid artery of the rabbit
108. A comparative study of policosanol vs lovastatin on intimal thickening in rabbit cuffed carotid artery
109. Effect of policosanol on cerebral ischemia in Mongolian gerbils: Role of prostacyclin and thromboxane A2
110. Effect of policosanol on cerebral ischemia in Mongolian gerbils
111. Lowering of serum cholesterol in hypercholesterolemic humans by tocotrienols (palmvitee)
112. Response of hypercholesterolemic subjects to administration of tocotrienols
113. Antioxidant effects of tocotrienols in patients with hyperlipidemia and carotid stenosis
114. Palm tocotrienols protect Apo E +/- mice from diet-induced atheroma formation
115. Effects of a high-complex-carbohydrate, low-fat, low-cholesterol diet on levels of serum lipids and estradiol
116. Effects of life-style modification on serum lipids
117. Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects
118. Effects of dietary cholesterol on serum cholesterol: A meta-analysis and review
119. Hypercholesterolemia and atherosclerosis: Effects of dietary protein
120. Protein and atherosclerosis
121. Metabolic effects of a low-glycemic-index diet
122. A strategy to arrest and reverse coronary artery disease: A 5-year longitudinal study of a single physician's practice
123. Updating a 12-year experience with arrest and reversal therapy for coronary heart (disease an overdue requiem for palliative cardiology)
124. Intensive lifestyle changes for reversal of coronary heart disease
125. Role of diet and exercise in the management of hyperinsulinemia and associated atherosclerotic risk factors
126. High-carbohydrate, high-fiber diets increase peripheral insulin sensitivity in healthy young and old adults
127. Toward improved management of NIDDM: A randomized, controlled, pilot intervention using a lowfat, vegetarian diet
128. Blood rheology in vegetarians
129. Favorable impact of a vegan diet with exercise on hemorheology - Implications for control of diabetic neuropathy
130. The effect of endocrine therapy with medroxyprogesterone acetate, 4-hydroxyandrostenedione or tamoxifen on plasma concentrations of insulin-like growth factor (IGF)-I, IGF-II and IGFBP-1 in women with advanced breast cancer
131. LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: The Strong Heart Study
132. Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study
133. Failure to reduce cholesterol as explanation for the limited efficacy of antihypertensive treatment in the reduction of CHD. Examination of the evidence from six hypertension intervention trials
134. Diet and exercise in the treatment of NIDDM. The need for early emphasis
135. The endogenous cofactors, thioctic acid and dihydrolipoic acid, are neuroprotective against NMDA and malonic acid lesions of striatum
136. Blood pressure in vegetarians
137. Vegetarian diet and blood pressure levels: Incidental or causal association?
138. In cholesterol lowering, moderation kills
139. Is atherosclerosis an arginine deficiency disease?
140. Endothelial dysfunction in hypercholesterolemia is reversed by a nutritional product designed to enhance nitric oxide activity
141. Nutritional therapy for peripheral arterial disease: A double-blind, placebo-controlled, randomized trial of HeartBar
142. Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans
143. Omega-3 fatty acids in the prevention-management of cardiovascular disease
144. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial
145. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease
146. Randomized, double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction
147. Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure
148. Long-term effect of taurine in congestive heart failure: Preliminary report
149. Effects of increased adrenomedullary activity and taurine in young patients with borderline hypertension
150. Taurine modulates platelet aggregation in cats and humans
151. Blood pressure and metabolic changes during dietary L-arginine supplementation in humans
152. Can we recommend fish oil for hypertension?
153. Coenzyme Q10 in essential hypertension
154. A possible protective effect of nut consumption on risk of coronary heart disease. The Adventist Health Study
155. Does potassium supplementation lower blood pressure? A meta-analysis of published trials
156. Vascular effects of L-arginine: Anything beyond a substrate for the NO- synthase?
157. Atherogenesis and the arginine hypothesis
158. Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by L-arginine after chronic statin treatment
159. N-3 fatty acids from fish oil. Effects on plasma lipoproteins and hypertriglyceridemic patients
160. L-carnitine treatment for congestive heart failure - Experimental and clinical study
161. Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: A double-blind, cross-over study
162. Effects of L-carnitine on exercise tolerance in chronic stable angina: A multicenter, double-blind, randomized, placebo controlled crossover study
163. A randomised, double-blind, placebo-controlled trial of L-carnitine in suspected acute myocardial infarction
164. The role of vitamins in the pathogenesis and treatment of hyperhomocyst(e)inaemia
165. Is there a potential therapeutic role for vitamin E or other antioxidants in atherosclerosis?
166. Oxidants downstream from superoxide inhibit nitric oxide production by vascular endothelium - A key role for selenium-dependent enzymes in vascular health
167. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes
168. The effect of chromium supplementation on carbohydrate metabolism and body composition
169. Up-regulation of endothelial nitric oxide activity as a central strategy for prevention of ischemic stroke - Just say NO to stroke!